|
|
Article: Inex Presents Interim NHL Trial Results With 100% Response.
- Article from:
- BIOWORLD Today
- Article date:
- November 4, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Senior Staff Writer
Inex Pharmaceuticals Corp. presented interim results from an ongoing non-Hodgkin's lymphoma Phase II trial at the American Society of Clinical Oncology meeting in Orlando, Fla., and the results showed all patients responded to the treatment.
Inex, of Vancouver, British Columbia, presented interim results for its lead product, Onco TCS, in combination therapy for the first-line treatment of aggressive non-Hodgkin's lymphoma. Results from 26 patients in the Phase II trial showed all patients responded to treatment. Twenty-five patients of the 26 completely responded to therapy and had all their tumors eliminated; one patient partially ...